# CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4

Study · id `cardio:ct-nct05066789` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05066789](<https://clinicaltrials.gov/study/NCT05066789>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05066789

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 100 participants.

## Technical summary

Registry record NCT05066789. Randomized; no masking; primary purpose treatment. Start 2022-01-17 (actual); primary completion 2024-03-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05066789, source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)
- Started: 2022-01-17 (actual) (ClinicalTrials.gov record NCT05066789, source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)
- Primary completion: 2024-03-22 (actual) (ClinicalTrials.gov record NCT05066789, source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)
- Completion: 2024-03-22 (actual) (ClinicalTrials.gov record NCT05066789, source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05066789, source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05066789-2025-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
- Acronym: SMART-CHOICE4
- Condition: Coronary Artery Disease
- Intervention (Device): Type of stent
- Intervention (Drug): Duration of DAPT
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 273e337451d1e85cfa242bca8f1acd4345344e76fa7e3b1ba564c280d83a9c4b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
